ADMA Biologics (ADMA) reported Q4 earnings Monday of $0.46 per diluted share, compared with a loss of $0.08 a year earlier.
Three analysts polled by FactSet expected $0.15.
Revenue in the three months ended Dec. 31 rose to $117.5 million from $73.9 million a year earlier.
Three analysts surveyed by FactSet expected $112.8 million.
The company boosted its 2025 revenue forecast to $490 million from $465 million and forecast 2026 revenue of $605 million.
Three analysts polled by FactSet expect revenue of $479.2 million in 2025 and $599 million in 2026.
The company's shares rose 6.2% in after-hours trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。